Key Points Non-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. GAAP revenue reached $687.5 million for Q2 2025, beating expectations by $33.6 million and ...

Sharp increase in mainland buying comes as trading and fundraising activity in the city rebounds after a multi-year slump.

Breathe in, breathe out. The 2025 Trade Deadline certainly kept everyone across baseball on their toes, and we at MLB ...

Foreign institutional investors are raising stakes in these government-backed companies. We explore what is fuelling the interest.

EQT Corporation (NYSE:EQT) is one of the stocks Jim Cramer highlighted as potential winners from the US-EU deal. Cramer ...

Energy Transfer LP (NYSE:ET) is one of the stocks Jim Cramer highlighted as potential winners from the US-EU deal. Cramer ...

More deals are likely coming down the pipeline for Biogen Inc. as the company looks to build out its early-stage pipeline.

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Gentherm’s Ford wins, China growth, and strong pipeline support long-term potential despite near-term margin pressure from ...

Year to date, the stock is now down around 12% (as of July 25) as it recently hit a new 52-week low of $410.11. While it has ...

Neurocrine Biosciences continues strong with Ingrezza and Crenessity growth, plus a promising pipeline in MDD and ...

Growth has slowed somewhat in 2025 due to lower European Union imports, tepid growth in the liquified natural gas (LNG) sector and storage injection issues in the EU and Asia. Still, the AI infusion ...